We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 19, 2022

Updated Overall Survival of Ribociclib Plus Endocrine Therapy vs Endocrine Therapy Alone in Pre- and Perimenopausal Patients With HR+/HER2− Advanced Breast Cancer

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Updated Overall Survival of Ribociclib Plus Endocrine Therapy vs Endocrine Therapy Alone in Pre- and Perimenopausal Patients With HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Clin. Cancer Res 2021 Dec 29;[EPub Ahead of Print], YS Lu, SA Im, M Colleoni, F Franke, A Bardia, F Cardoso, N Harbeck, S Hurvitz, L Chow, J Sohn, KS Lee, S Campos-Gomez, R Villanueva Vazquez, KH Jung, KG Babu, P Wheatley-Price, M De Laurentiis, YH Im, S Kuemmel, N El-Saghir, R O'Regan, C Gasch, N Solovieff, C Wang, Y Wang, A Chakravartty, Y Ji, D Tripathy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading